356 related articles for article (PubMed ID: 34002026)
21. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
24. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.
Moreno-García E; Rico E; Albiach L; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Linares L; Macay I; Meira F; Mensa J; Moreno A; Morata L; Puerta-Alcalde P; Rojas J; Solá M; Torres B; Torres M; Tomé A; Tuset M; Castro P; Fernández S; Nicolás JM; Almuedo-Riera A; Muñoz J; Fernandez-Pittol M; Marcos MA; Soy D; Martínez JA; García F; Soriano A
Rev Esp Quimioter; 2021 Jun; 34(3):238-244. PubMed ID: 33829722
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.
Aziz M; Haghbin H; Abu Sitta E; Nawras Y; Fatima R; Sharma S; Lee-Smith W; Duggan J; Kammeyer JA; Hanrahan J; Assaly R
J Med Virol; 2021 Mar; 93(3):1620-1630. PubMed ID: 32918755
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.
Peng J; Fu M; Mei H; Zheng H; Liang G; She X; Wang Q; Liu W
Rev Med Virol; 2022 May; 32(3):e2295. PubMed ID: 34558756
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab in the treatment of COVID-19-a meta-analysis.
Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
Sarfraz A; Sarfraz Z; Sarfraz M; Aftab H; Pervaiz Z
Turk J Med Sci; 2021 Jun; 51(3):890-897. PubMed ID: 33244947
[TBL] [Abstract][Full Text] [Related]
29. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
Cortegiani A; Ippolito M; Greco M; Granone V; Protti A; Gregoretti C; Giarratano A; Einav S; Cecconi M
Pulmonology; 2021; 27(1):52-66. PubMed ID: 32713784
[TBL] [Abstract][Full Text] [Related]
30. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R; Pawlowski CF; O'Horo JC; Arndt LL; Arndt RF; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan PJ; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411003
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection.
Ivan Hariyanto T; Kurniawan A
J Med Virol; 2021 Mar; 93(3):1832-1836. PubMed ID: 33241872
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
Hariyanto TI; Hardyson W; Kurniawan A
Drug Res (Stuttg); 2021 May; 71(5):265-274. PubMed ID: 33401328
[TBL] [Abstract][Full Text] [Related]
34. Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients.
Pijls BG; Jolani S; Atherley A; Dijkstra JIR; Franssen GHL; Hendriks S; Yi-Wen Yu E; Zalpuri S; Richters A; Zeegers MP
F1000Res; 2022; 11():5. PubMed ID: 35514606
[No Abstract] [Full Text] [Related]
35. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
37. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
38. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
39. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.
Kotak S; Khatri M; Malik M; Malik M; Hassan W; Amjad A; Malik F; Hassan H; Ahmed J; Zafar M
Cureus; 2020 Oct; 12(10):e10869. PubMed ID: 33178522
[TBL] [Abstract][Full Text] [Related]
40. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
Rodríguez-Baño J; Pachón J; Carratalà J; Ryan P; Jarrín I; Yllescas M; Arribas JR; Berenguer J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Clin Microbiol Infect; 2021 Feb; 27(2):244-252. PubMed ID: 32860964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
